Charles Jiang on Elizabeth Nally’s Adjuvant Pembrolizumab in RCC Abstract
Adjuvant pembrolizumab has emerged as a significant consideration for patients with high-risk renal cell carcinoma (RCC) following nephrectomy. Recent discourse, including analysis by Charles Jiang on Elizabeth Nally’s work, highlights ... Read More